Company: PBH
Filing Date: 2025-05-09
Form Type: 10-K
Source: 0001295947-25-000017
Chunk: 76

Company: Prestige Consumer Healthcare Inc.
Filing Date: 2025-05-09
Form: 10-K
Item: Item 7
Chunk 76
---
 2024.

(In thousands)Increase (Decrease)Contribution Margin2025%2024%Amount%North American OTC Healthcare$401,708 41.8 $397,405 41.5 $4,303 1.1 International OTC Healthcare77,032 43.3 73,728 44.1 3,304 4.5  $478,740 42.1 $471,133 41.9 $7,607 1.6 

North American OTC Healthcare Segment

Contribution margin for the North American OTC Healthcare segment increased $4.3 million, or 1.1%, during 2025 versus 2024.  As a percentage of North American OTC Healthcare revenues, contribution margin for the North American OTC Healthcare segment increased to 41.8% during 2025 from 41.5% during 2024.  The contribution margin increase as a percentage of revenues was primarily due to the increase in gross profit margin noted above and decreased advertising and marketing spend in North America during 2025.  

International OTC Healthcare Segment

Contribution margin for the International OTC Healthcare segment increased $3.3 million, or 4.5%, during 2025 versus 2024. As a percentage of International OTC Healthcare revenues, contribution margin for the International OTC Healthcare segment decreased to 43.3% during 2025 from 44.1% during 2024.  The contribution margin decrease as a percentage of revenues was primarily due to an increase in advertising and marketing spend internationally in 2025.

General and Administrative

General and administrative expenses were $108.2 million for 2025 versus $106.2 million for 2024.  The increase in general and administrative expenses was primarily due to increases in compensation costs and professional fees.

Depreciation and Amortization

Depreciation and amortization expense was $21.3 million for 2025 versus $22.6 million for 2024.  The decrease in depreciation and amortization expenses was primarily due to a decrease in amortization expense due to certain intangible assets being fully amortized during 2025.  

38

Tradename Impairment

In 2025, our annual impairment test resulted in total impairment charges of $12.5 million.  This includes $6.6 million related to non-strategic indefinite-lived intangible assets and $5.